Science & Research
Grifols Launches FDA-Approved Fibrinogen Concentrate FESILTY in U.S.
The plasma-derived concentrate targets a rare bleeding disorder affecting both pediatric and adult patients — a niche b…
All 513 stories
Condition-Specific Health
CAR-T Cell Therapy LB2501 Shows Early Clinical Signal in B-Cell Lymphoma
The dual-targeting CD19/CD20 mechanism marks a potential first-in-class approach, though the asset sits outside convent…
Health & Wellness
Humacyte Bioengineered Vessel Posts Phase 3 Win in Dialysis Access
The V012 data add clinical weight to acellular tissue engineering, a frontier with implications for bioactive and regen…
Condition-Specific Health
Anti-TL1A Therapy SPY002 Hits Primary Endpoint in UC Induction Trial
Gut-inflammation targeting moves further into clinical validation — with implications for next-gen functional ingredien…
Industry & Business
Off-Topic Submission: No Functional Ingredient or Nutraceutical News Found
Submitted content falls outside Functional News editorial scope. No ingredient, clinical nutrition endpoint, or finishe…
Ingredients & Formulation
Vaxart Oral Vaccine Platform Heads to BIO 2026 Showcase
The clinical-stage biotech's tablet-based delivery approach draws attention as mucosal immunization research intersects…
Regulatory & Policy
Editor's Note: This Release Falls Outside Functional News Coverage
Functional News covers ingredients, finished formulations, and regulatory developments in functional foods, dietary sup…
Ingredients & Formulation
Dyadic C1 Platform Gains Traction in Nutraceutical Biomanufacturing
Originally developed for vaccine biologics, the C1 platform's high-yield fermentation economics are attracting finished…
Condition-Specific Health
Pasithea Therapeutics to Exhibit at 2026 NF Conference
The appearance marks a cross-sector moment as biotech pipelines intersect with functional and nutraceutical research in…
Industry & Business
Elicio Therapeutics AMPLIFY-7P Phase 2 Data: mKRAS Cancer Vaccine Update
This press release describes a clinical-stage oncology immunotherapy — outside Functional News editorial scope. No func…
Condition-Specific Health
Lexeo LX2006 Gene Therapy Trial Targets Cardiac Endpoint in Friedreich Ataxia
The open-label study design and 6-month topline readout signal an accelerated path toward regulatory submission for the…
Science & Research
Pharvaris HAE Drug Data Presented at EAACI 2026
The late-stage biopharmaceutical asset targets bradykinin-mediated angioedema — a rare-disease space with limited oral …